Healthcare
UROGEN PHARMA LTD
Ticker: URGN
|
Exchange: US
|
Composite FIGI: BBG00GFCC613
Total Alternative Signals
1signals tracked
Weighted Sentiment
-0.50weighted index
Avg Materiality Score
3.0/ 5.0 scale
Signal Distribution
0▲|0■|1▼
Alternative Data Signal Feed
Unlock Alternative Signals Feed
Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for UROGEN PHARMA LTD. Programmatic API and Webhooks available.
Talent PivotBearish
Filing Date: 2026-06-15
Signal Event Report - FIGI BBG00GFCC613
UroGen Pharma's Chief Medical Officer sold 5,222 shares, an insider transaction that occurred after a period of strong share price performance. This sale could be interpreted by investors as a signal regarding the executive's outlook on the company's future valuation.
Quantitative Investment Thesis
The insider sale by the CMO introduces a potential cautionary note for investors, suggesting that a key executive might see limited upside or believe the stock is fully valued after recent gains. This could prompt a re-evaluation of the long-term growth prospects and valuation.
Materiality & Sentiment Scores
Sentiment: -0.5
Materiality: 3 / 5
Source Document: https://www.fool.com/coverage/filings/2026/06/14/is-urogen-pharma-a-stock-to-sell-after-its-chief-medical-officer-unloaded-5-222-shares/?.tsrc=rss